Equity Profile

CRSP

CRISPR Therapeutics AG

Health CareBiotechnology$5.1B

Aug10Mon

Pre-Earnings Brief

UpcomingQ2-2026After Close5:00 PM EDT

Company Snapshot

CRISPR Therapeutics AG is a biotechnology company focused on developing transformative gene-based medicines using CRISPR technology. As part of the health care sector, it aims to address serious diseases by editing genes, which is a significant advancement in medical science.

Key Metrics to Watch

EPS

Earnings per share will indicate the company's profitability and how well it is managing its costs.

N/A

Revenue

Revenue figures will provide insight into the company's sales performance and market demand for its products.

N/A

Wall Street expectations, options signals, track record, and call prep available with Pro.

CRSP Q2-2026 Earnings Preview

Context

Company Snapshot

Earnings Scorecard·Last 8Q

EPS Beat Streak

EPS Beat Rate

38%

Avg EPS Surprise

-4.69%

Avg Stock Reaction

-0.54%

Last Quarter Recap

In Q1 2026, CRISPR reported an EPS of -$1.28, which was worse than analysts' expectations. Despite the miss, the stock rose by 3.78% the following day.

Management Promises & Guidance

Expectations

Wall Street Expectations

Investors are cautious ahead of the earnings report, given the company's recent history of missing EPS estimates. The market is looking for any signs of improvement in financial performance.

Bull Case

If CRISPR can demonstrate progress in its gene-editing therapies and show a smaller loss than expected, it could boost investor confidence and drive the stock higher.

Bear Case

On the other hand, continued losses and lack of revenue growth could lead to further declines in stock price, especially if the company fails to provide a clear path to profitability.

Expectations

Two Questions That Matter

The print will turn on these two things.

What will be the EPS for Q2 2026?

Given the company's recent history of missing EPS estimates, this number will be critical in assessing financial health and investor sentiment.

What revenue growth can CRISPR report this quarter?

Revenue growth is essential for demonstrating market demand for its therapies and could influence future investment and stock performance.

Edge

What the Street Is Missing

Why consensus could be wrong

The Street may underestimate the potential for CRISPR's therapies to gain traction in the market, particularly if they can demonstrate any progress in clinical trials.

Supporting Evidence

The options market is pricing a significant move, indicating that investors are anticipating a more volatile reaction than historical averages suggest.

CRISPR's recent stock performance has shown resilience despite poor earnings, suggesting a potential for recovery.

The company has a strong pipeline of therapies that could lead to future revenue growth, which may not be fully reflected in current estimates.

Key Risk

If CRISPR can report any positive developments in its clinical trials, it could significantly shift investor sentiment.

Edge

Thesis-Break Levels

Pre-commit to what would confirm each case.

The core debate this quarter revolves around whether CRISPR can show signs of financial recovery or if it will continue to struggle with losses.

Bull Confirmed If

A smaller loss than -$1.28 EPS could signal improved operational efficiency and investor confidence.

Bear Confirmed If

A larger loss than expected, particularly if it exceeds -$1.28 EPS, would raise concerns about the company's viability.

Pre-Earnings Positioning

Options Market

Implied Move

±26.4%

Historical Avg

±3.5%

Pricing rich

The options market is pricing in a significant move, suggesting that investors expect volatility around the earnings announcement.

Options are pricing ±26.4% while CRSP has averaged ±3.5% over the last 8 prints — setup is pricing rich.

Detail

ATM IV

0.6%

30d HV

61.0%

Calls (499K)P/C Ratio: 0.53Puts (93K)

Preparation

Post-Print Playbook

Likely market behavior by outcome — not investment advice.

Beat & Raise

If CRISPR beats expectations, history suggests a modest positive reaction, potentially confirming a turnaround in financial performance.

In-Line / Cautious

If results are in line with expectations, the stock may remain stable but could be influenced by management's commentary on future prospects.

Miss

If CRISPR misses expectations, history suggests a negative reaction, with the stock likely to decline as investor confidence wanes.

Earnings Track Record

Preparation

What to Listen For

Call Prep

1Updates on the progress of ongoing clinical trials.
2Any new partnerships or collaborations that could enhance product development.
3Management's outlook on future revenue growth and profitability.
4Details on cost management strategies to reduce losses.
5Insights into market demand for CRISPR's therapies.

See the full picture

AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.

No charge today · Auto-bills $8/mo after 7 days · Cancel anytime

More Earnings This Week

5 Reports

Tempus AI, Inc.

Company Snapshot

Key Metrics to Watch

EPS

Earnings per share will indicate the company's profitability and how well it is managing its costs.

N/A

Revenue

Revenue figures will provide insight into the company's sales performance and market demand for its products.

N/A

Wall Street expectations, options signals, track record, and call prep available with Pro.

CRSP Q2-2026 Earnings Preview

Context

Company Snapshot

Earnings Scorecard·Last 8Q

EPS Beat Streak

EPS Beat Rate

38%

Avg EPS Surprise

-4.69%

Avg Stock Reaction

-0.54%

Last Quarter Recap

In Q1 2026, CRISPR reported an EPS of -$1.28, which was worse than analysts' expectations. Despite the miss, the stock rose by 3.78% the following day.

Management Promises & Guidance

Expectations

Wall Street Expectations

Investors are cautious ahead of the earnings report, given the company's recent history of missing EPS estimates. The market is looking for any signs of improvement in financial performance.

Bull Case

If CRISPR can demonstrate progress in its gene-editing therapies and show a smaller loss than expected, it could boost investor confidence and drive the stock higher.

Bear Case

On the other hand, continued losses and lack of revenue growth could lead to further declines in stock price, especially if the company fails to provide a clear path to profitability.

Expectations

Two Questions That Matter

The print will turn on these two things.

What will be the EPS for Q2 2026?

Given the company's recent history of missing EPS estimates, this number will be critical in assessing financial health and investor sentiment.

What revenue growth can CRISPR report this quarter?

Revenue growth is essential for demonstrating market demand for its therapies and could influence future investment and stock performance.

Edge

What the Street Is Missing

Why consensus could be wrong

The Street may underestimate the potential for CRISPR's therapies to gain traction in the market, particularly if they can demonstrate any progress in clinical trials.

Supporting Evidence

The options market is pricing a significant move, indicating that investors are anticipating a more volatile reaction than historical averages suggest.

CRISPR's recent stock performance has shown resilience despite poor earnings, suggesting a potential for recovery.

The company has a strong pipeline of therapies that could lead to future revenue growth, which may not be fully reflected in current estimates.

Key Risk

If CRISPR can report any positive developments in its clinical trials, it could significantly shift investor sentiment.

Edge

Thesis-Break Levels

Pre-commit to what would confirm each case.

The core debate this quarter revolves around whether CRISPR can show signs of financial recovery or if it will continue to struggle with losses.

Bull Confirmed If

A smaller loss than -$1.28 EPS could signal improved operational efficiency and investor confidence.

Bear Confirmed If

A larger loss than expected, particularly if it exceeds -$1.28 EPS, would raise concerns about the company's viability.

Pre-Earnings Positioning

Options Market

Implied Move

±26.4%

Historical Avg

±3.5%

Pricing rich

The options market is pricing in a significant move, suggesting that investors expect volatility around the earnings announcement.

Options are pricing ±26.4% while CRSP has averaged ±3.5% over the last 8 prints — setup is pricing rich.

Detail

ATM IV

0.6%

30d HV

61.0%

Calls (499K)P/C Ratio: 0.53Puts (93K)

Preparation

Post-Print Playbook

Likely market behavior by outcome — not investment advice.

Beat & Raise

If CRISPR beats expectations, history suggests a modest positive reaction, potentially confirming a turnaround in financial performance.

In-Line / Cautious

If results are in line with expectations, the stock may remain stable but could be influenced by management's commentary on future prospects.

Miss

If CRISPR misses expectations, history suggests a negative reaction, with the stock likely to decline as investor confidence wanes.

Earnings Track Record

Preparation

What to Listen For

Call Prep

1Updates on the progress of ongoing clinical trials.
2Any new partnerships or collaborations that could enhance product development.
3Management's outlook on future revenue growth and profitability.
4Details on cost management strategies to reduce losses.
5Insights into market demand for CRISPR's therapies.